title: Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.
abstract: Neurologic and psychiatric manifestations are prevalent in children and adults with lupus (labeled by convention neuropsychiatric systemic lupus erythematosus or NPSLE). However, there is a paucity of data on the evaluation and management of NPSLE in youth, with only a few publications describing the use of atypical antipsychotics in children and adolescents with lupus. In children, aripiprazole, a D2/5-HT1A partial agonist, appears to cause less prominent metabolic derangements than other second-generation antipsychotics. This agent may be an important tool in the treatment of pediatric patients with lupus who are at risk for weight gain and dyslipidemia due to disease and corticosteroid effects. The authors present two cases in which psychiatric symptoms associated with treatment-refractory lupus responded to aripiprazole pharmacotherapy.
authors.affiliation: Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
authors.forename: Eyal
authors.initials: E
authors.lastname: Muscal
authors.forename: Leng
authors.initials: L
authors.lastname: Bang
authors.forename: Ayesha
authors.initials: A
authors.lastname: Mian
authors.forename: Toi Blakley
authors.initials: TB
authors.lastname: Harris
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000068180:Aripiprazole; D050171:Dyslipidemias / Q000209:etiology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D020945:Lupus Vasculitis, Central Nervous System / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D009483:Neuropsychological Tests; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D016896:Treatment Outcome; D015430:Weight Gain
chemical_list: D000305:Adrenal Cortex Hormones; D014150:Antipsychotic Agents; D007166:Immunosuppressive Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole